The impact of comorbidity on the survival of postmenopausal women with breast cancer

被引:47
作者
Nagel, G
Wedding, U
Hoyer, H
Röhrig, B
Katenkamp, D
机构
[1] Deutsch Krebsforschungszentrum, Div Clin Epidemiol, D-69120 Heidelberg, Germany
[2] Univ Jena, Ctr Comprehens Canc, Field Study Breast Canc, D-6900 Jena, Germany
[3] Univ Jena, Clin Internal Med 2, D-6900 Jena, Germany
[4] Univ Jena, Inst Med Stat Comp Sci & Documentat, D-6900 Jena, Germany
关键词
breast cancer; comorbidity; survival;
D O I
10.1007/s00432-004-0594-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim was to assess the impact of comorbidity on survival of postmenopausal women with breast cancer diagnosis in the period 1995-1997. Methods: The level of comorbidity was described by the methods suggested by Satariano and Charlson. Cox's proportional hazard models were used to explore the impact of comorbidity on all-cause mortality. Results: After a median follow-up time of 52 months, an increasing level of comorbidity was associated with a higher all-cause mortality. Compared to patients without comorbid conditions, the hazard ratio of death (HR) was 1.2 (95% Cl: 0.8-1.7) for Satariano index 1 and HR 2.3 (95% Cl: 1.5-3.5) for Satariano index greater than or equal to2, and HR 1.6 and 2.1 for the Charlson comorbidity index, respectively. Independent of comorbidity, the treatment pattern had a strong impact on survival. The level of comorbidity has an influence on the 3-year survival of postmenopausal women with breast cancer. Conclusions: Long-term follow-up is required to appraise these findings in relation to treatment strategies.
引用
收藏
页码:664 / 670
页数:7
相关论文
共 42 条
[1]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[2]   Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993-1996 [J].
Coebergh, JWW ;
Janssen-Heijnen, MLG ;
Post, PN ;
Razenberg, PPA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (12) :1131-1136
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Practical considerations on the use of the Charlson comorbidity index with administrative data bases [J].
DHoore, W ;
Bouckaert, A ;
Tilquin, C .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (12) :1429-1433
[5]   Tumor characteristics and clinical outcome of elderly women with breast cancer [J].
Diab, SG ;
Elledge, RM ;
Clark, GM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) :550-556
[6]   Primary breast cancer therapy in six regions of Germany [J].
Engel, J ;
Nagel, G ;
Breuer, E ;
Meisner, C ;
Albert, US ;
Strelocke, K ;
Sauer, H ;
Katenkamp, D ;
Mittermayer, C ;
Heidemann, E ;
Schulz, KD ;
Kunath, H ;
Lorenz, W ;
Hölzel, D .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) :578-585
[7]   Comorbidity and functional status are independent in older cancer patients [J].
Extermann, M ;
Overcash, J ;
Lyman, GH ;
Parr, J ;
Balducci, L .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1582-1587
[8]   Measurement and impact of comorbidity in older cancer patients [J].
Extermann, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (03) :181-200
[9]   PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE [J].
FEINSTEIN, AR .
JOURNAL OF CHRONIC DISEASES, 1970, 23 (07) :455-+
[10]   Causes and consequences of comorbidity: A review [J].
Gijsen, R ;
Hoeymans, N ;
Schellevis, FG ;
Ruwaard, D ;
Satariano, WA ;
van den Bos, GAM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (07) :661-674